Objective: To evaluate vaccine safety, antibody response, and nonspecific lymphocyte blastogenesis following inoculation of a commercial monovalent live attenuated bluetongue virus (BTV) serotype 2 vaccine in goats.
Animals: 12 nonpregnant and nonlactating Saanen goats.
Procedure: 6 goats were inoculated with the monovalent live attenuated BTV serotype 2 vaccine, which has been widely used in Italy during the proceding 2 years. The other 6 goats were unvaccinated and represented negative controls. Nonspecific lymphocyte blastogenesis was evaluated 14 and 7 days before and 7, 21, and 49 days after vaccination by measuring DNA synthesis in peripheral blood mononuclear cells (PBMCs) stimulated with phytohemagglutinin, concanavalin-A, and pokeweed mitogen. On the same days as lymphocyte blastogenesis, blood samples were taken to determine serum concentrations of anti-BTV antibodies.
Results: During the 7 weeks following vaccination, PBMCs obtained from vaccinated goats had a significantly decreased response to mitogens in terms of DNA synthesis, compared with PBMCs from the same goats before vaccination. Conversely during the experiment, no significant change was found in the response of the PBMCs obtained from unvaccinated goats. Starting from 21 days after vaccination, serum from vaccinated goats had anti-BTV antibodies. No anti-BTV antibodies were detected in the serum from unvaccinated goats.
Conclusions And Clinical Relevance: Inoculation of goats with the monovalent live attenuated BTV serotype 2 vaccine described herein resulted in a profound depression of nonspecific lymphocyte blastogenesis, which might compromise the resistance of vaccinated goats to pathogens.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2460/ajvr.2004.65.1331 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SLAMF7 defines subsets of human effector CD8 T cells.
Sci Rep
December 2024
Singapore Immunology Network (SIgN), Agency for Science Technology and Research (A*STAR), Immunos Building, 8A Biomedical Grove, Biopolis, Republic of Singapore.
Long-term control of viral replication relies on the efficient differentiation of memory T cells into effector T cells during secondary immune responses. Recent findings have identified T cell precursors for both memory and exhausted T cells, suggesting the existence of progenitor-like effector T cells. These cells can persist without antigenic challenge but expand and acquire effector functions upon recall immune responses.
View Article and Find Full Text PDFCombined transcriptome and metabolome analysis of stable knockdown and overexpression of the CD8A gene in chicken T lymphocytes.
Poult Sci
December 2024
Yunnan Rural Revitalizing Education Institute, Yunnan Open University, Kunming 650101, Yunnan Province, PR China; Key Laboratory of Buffalo Genetics, Breeding and Reproduction Technology, Guangxi Bufialo Research, Institute, Chinese Academy of Agricultural Sciences, Nanning 530001, PR China; College of Animal Science and Technology, Yunnan Agricultural University, Kunming 650201, Yunnan Province, PR China. Electronic address:
CD8 subunit alpha (CD8A) is an important gene in immunity and is involved in the functional regulation of T lymphocytes. However, the specific role and regulatory mechanism of CD8A in chicken T lymphocytes remain unknown. In this study, we overexpressed and interfered with CD8A in chicken T lymphocytes and found that interfering with CD8A expression inhibited the proliferation and induced the apoptosis of T lymphocytes and that the overexpression of CD8A promoted T lymphocyte activation.
View Article and Find Full Text PDFIdentification of Early and Late Responders to Anti-IL-13 Antibody Tralokinumab in Atopic Dermatitis: A Real-World Japanese Study.
Dermatitis
December 2024
From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Tralokinumab, an anti-IL-13 antibody, is an effective treatment for patients with atopic dermatitis (AD). However, predictive factors for responders to tralokinumab remain unclear in real-world practice. This study aimed to identify predictive factors for early and late responders to tralokinumab treatment.
View Article and Find Full Text PDFProspects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities.
Adv Respir Med
December 2024
JSC National Scientific Medical Center, Astana 010009, Kazakhstan.
This review explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer.
View Article and Find Full Text PDFCryoablation plus chemotherapy regimen enhance anti-tumor immune response in a mouse model of Lewis lung cancer.
Int J Hyperthermia
December 2024
Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Background: Cryoablation (cryo) is a local anti-tumor method and activation of immunity is one of its mechanisms, but it is affected by many factors. Numerous studies have proved that combination therapy based on cryo can activate immunity more effectively and synergistically. Cryo combined with chemotherapy(chemo) has been proven to improve the quality of life and prolong survival of tumor patients, but the immune effect is still unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!